AYTU · XBRL financial data

Aytu Biopharma financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (AYTU's year ends in late June)

In thousands of dollars	FY 2021Jun 30, 2021	FY 2022Jun 30, 2022	FY 2023Jun 30, 2023	FY 2024Jun 30, 2024	FY 2025Jun 30, 2025	FY 2026Jun 30, 2026
Revenue from contracts with customers	65,632	96,669	107,399	81,002	66,382	57,570
Cost of revenue	36,432	44,386	—	—	—	—
Cost of goods and services sold	—	44,386	40,767	26,416	20,551	20,752
Gross profit	29,200	52,283	66,632	54,586	45,831	36,818
Research and development	5,623	14,439	4,095	2,791	1,326	0
General and administrative	25,500	31,167	28,630	22,514	17,379	19,272
Total operating expenses	88,070	163,844	83,697	59,840	53,658	45,133
Operating income (loss)	(58,870)	(111,561)	(17,065)	(5,254)	(7,827)	(8,315)
Interest expense	—	900	4,963	4,792	3,703	1,895
Other income (expense)	(2,050)	(862)	(4,779)	568	(512)	713
Income tax expense (benefit)	259	(110)	0	1,768	437	21
Net income (loss)	(58,289)	(110,173)	(17,051)	(15,844)	(13,562)	(14,252)
Earnings per share, basic‡ USD per share	(69.60)	(67.80)	(5.11)	(2.86)	(2.16)	(1.16)
Earnings per share, diluted‡ USD per share	(69.60)	(75.00)	(5.11)	—	—	—
Weighted average shares, basic‡ thousands of shares	837	1,470	3,340	5,538	6,280	12,319
Weighted average shares, diluted‡ thousands of shares	837	1,470	3,340	—	—	—

‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (January 2023); filings made before it reported them unadjusted.

Fiscal years (AYTU's year ends in late June)

In thousands of dollars	FY 2021Jun 30, 2021	FY 2022Jun 30, 2022	FY 2023Jun 30, 2023	FY 2024Jun 30, 2024	FY 2025Jun 30, 2025	FY 2026Jun 30, 2026
Cash and cash equivalents	49,649	19,360	22,985	20,006	30,952	26,308
Accounts receivable	28,176	21,712	28,937	23,617	31,155	22,779
Inventory	16,339	10,849	11,995	12,633	11,434	6,860
Prepaid and other current assets	—	—	—	5,097	5,638	5,814
Total current assets	105,234	59,929	72,832	61,891	79,179	61,761
Property and equipment, net	—	—	1,815	693	532	385
Right-of-use asset	3,563	3,271	2,054	829	1,061	857
Goodwill	65,802	0	0	—	—	—
Total assets	265,668	137,623	136,463	118,095	124,177	105,007
Accounts payable	19,255	—	13,478	10,440	10,601	11,284
Accrued liabilities	51,295	44,187	46,799	38,574	38,164	35,205
Current portion of long-term debt	—	—	85	1,857	1,857	1,857
Total current liabilities	109,438	64,442	69,015	62,228	63,064	54,659
Long-term debt	—	—	14,713	10,877	10,895	9,101
Lease liability, non-current	2,624	2,090	832	577	985	853
Total liabilities	128,100	91,531	97,106	—	—	—
Accumulated deficit	(178,299)	(288,472)	(304,129)	(319,973)	(333,535)	(347,787)
Total stockholders' equity	137,568	46,092	39,357	27,716	18,966	35,274
Total liabilities and equity	265,668	137,623	136,463	118,095	124,177	105,007
Common shares outstanding (cover page)‡ thousands of shares	1,378	3,122	5,530	6,149	9,912	10,867

‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (January 2023); filings made before it reported them unadjusted.

Fiscal years (AYTU's year ends in late June)

In thousands of dollars	FY 2021Jun 30, 2021	FY 2022Jun 30, 2022	FY 2023Jun 30, 2023	FY 2024Jun 30, 2024	FY 2025Jun 30, 2025	FY 2026Jun 30, 2026
Net income (loss)	(58,289)	(110,173)	(17,051)	(15,844)	(13,562)	(14,252)
Stock-based compensation	3,574	5,248	6,046	2,913	576	691
Depreciation and amortization	9,201	10,251	8,815	8,272	—	—
Net cash from operating activities	(25,964)	(28,823)	(5,129)	(1,388)	(1,937)	3,281
Purchases of property and equipment	—	—	—	329	228	29
Net cash from investing activities	(2,782)	(3,248)	(117)	(329)	(2,560)	(29)
Proceeds from issuing common stock	45,051	11,694	15,575	—	—	—
Proceeds from long-term debt	—	—	—	13,000	1,857	0
Repayments of long-term debt	—	—	96	15,722	1,857	1,857
Net cash from financing activities	30,314	1,530	8,871	(1,262)	15,443	(7,896)
Net change in cash	1,568	(30,541)	3,625	(2,979)	10,946	(4,644)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Aytu Biopharma	26,308	16,106*	4,406*	10.9M	—	Q4 FY26 10-KJun 30, 2026
Tenax Therapeutics	118,000	0*	(14,150)*	37.4M	8.3 quarters	Q2 FY26 10-QJun 30, 2026
Dyadic International	1,425	961	(1,818)*	36.4M	1.7 quarters	Q2 FY26 10-QJun 30, 2026
Nanoviricides	2,794	not reported	(2,122)*	25.5M	1.3 quarters	Q4 FY26 10-KJun 30, 2026
Lisata Therapeutics	10,443	0	(2,649)*	9.0M	3.9 quarters	Q2 FY26 10-QJun 30, 2026
Kala Bio	229	not reported	(1,535)*	19.3M	4.7 quarters	Q2 FY26 10-QJun 30, 2026
Lexaria Bioscience	3,500	0	(1,635)*	24.8M	2.2 quarters	Q3 FY26 10-QMay 31, 2026
Curis	5,073	0	(9,646)*	2.1M	0.5 quarters	Q2 FY26 10-QJun 30, 2026
Pulmatrix	2,168	not reported	(1,106)*	3.7M	2.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.